Bioorganic & Medicinal Chemistry Letters

Papers
(The H4-Index of Bioorganic & Medicinal Chemistry Letters is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Revisiting the dipeptidyl carboxypeptidase inhibitor captopril as a source of pan anti-trypanosomatid agents159
Design, synthesis and biological evaluation of alginate oligosaccharide derivatives92
Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors68
Discovery of DS-1093a: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia60
Editorial Board56
Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site50
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators49
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibit41
Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode40
Graphical Abstract TOC37
Editorial Board35
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor33
SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads31
Pyrazolo-1-carbothioamides as EGR-1–DNA binding disruptors30
Neuropilin 1-targeted near-infrared fluorescence probes for tumor diagnosis30
Design, synthesis and characterizations of prodrugs of brexanolone28
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model27
Development of a highly potent and selective degrader of LRRK226
Phytochemical investigation of Asarum sieboldii var. seoulense and the phenotypic profiles of its constituents against a Parkinson’s Disease olfactory cell line26
Design and structural optimization of thiadiazole derivatives with potent GLS1 inhibitory activity25
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor25
Improved synthesis and anticancer activity of a potent neuronal nitric oxide synthase inhibitor25
Contents continued24
Epigallocatechin and epigallocatechin-3-gallate are not inhibitors of tyrosinase24
Discovery of a macrocyclic FAK inhibitor GZD-257 for treatment of glioblastoma24
0.48830199241638